Screener
Castle Biosciences CSTL Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 100,934 | 97,443 |
| Operating lease assets | 14,424 | 14,795 |
| Goodwill and other intangible assets, net | 97,347 | 99,574 |
| Other assets – long-term | 4,278 | 3,769 |
| Total assets | $547,805 | $578,556 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Accounts payable | $15,038 | $18,711 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's deferred tax assets and other non-current assets?
- Castle Biosciences (CSTL) reported deferred tax assets and other non-current assets of $4.28M in Q1 2026.
- How has Castle Biosciences's deferred tax assets and other non-current assets changed year-over-year?
- Castle Biosciences's deferred tax assets and other non-current assets increased by 237.9% year-over-year, from $1.27M to $4.28M.
- What is the long-term trend for Castle Biosciences's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Castle Biosciences's deferred tax assets and other non-current assets has grown at a 19.7% compound annual growth rate (CAGR), from $1.54M to $3.77M.
Ask your AI about Castle Biosciences's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude